CASI Pharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -59.2% | -59.2% | — |
| FY2021 | -43.4% | -43.4% | -26.5% |
| FY2022 | -92.0% | -92.0% | -42.6% |
| FY2023 | -111.6% | -62.6% | -35.8% |
| FY2024 | -2,120.9% | -2,120.9% | -73.1% |
| FY2025 | 128.9% | 128.9% | -187.4% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -59.2% | -59.2% | — |
| FY2021 | -43.4% | -43.4% | -26.5% |
| FY2022 | -92.0% | -92.0% | -42.6% |
| FY2023 | -111.6% | -62.6% | -35.8% |
| FY2024 | -2,120.9% | -2,120.9% | -73.1% |
| FY2025 | 128.9% | 128.9% | -187.4% |